49. Systemic lupus erythematosus Clinical trials / Disease details


Clinical trials : 946 Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199

  
12 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-024069-30-BG
(EUCTR)
21/08/201208/08/2012A study to investigate the optimum dose, the efficacy and the safety of sifalimumab in adult patients with Systemic Lupus Erythematosus, a disease of the immune systemA Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults with Systemic Lupus Erythematosus Systemic Lupus Erythematosus
MedDRA version: 14.1;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Sifalimumab
Product Code: MEDI-545
INN or Proposed INN: sifalimumab
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
400Phase 2United States;Philippines;Spain;Thailand;Chile;Italy;United Kingdom;India;France;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Romania;Peru;Bulgaria;South Africa;Netherlands;Germany
2EUCTR2010-024069-30-DE
(EUCTR)
21/12/201119/05/2011A study to investigate the optimum dose, the efficacy and the safety of sifalimumab in adult patients with Systemic Lupus Erythematosus, a disease of the immune systemA Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults with Systemic Lupus Erythematosus Systemic Lupus Erythematosus
MedDRA version: 14.1;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Sifalimumab
Product Code: MEDI-545
INN or Proposed INN: sifalimumab
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
400Phase 2United States;Philippines;Spain;Thailand;Chile;Italy;United Kingdom;India;France;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Romania;Peru;South Africa;Bulgaria;Netherlands;Germany
3EUCTR2010-024069-30-NL
(EUCTR)
05/08/201104/05/2011A study to investigate the optimum dose, the efficacy and the safety of sifalimumab in adult patients with Systemic Lupus Erythematosus, a disease of the immune systemA Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults with Systemic Lupus Erythematosus Systemic Lupus Erythematosus
MedDRA version: 14.0;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Sifalimumab
Product Code: MEDI-545
INN or Proposed INN: sifalimumab
AstraZeneca ABNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
544Phase 2Hungary;Germany;Netherlands;France;Chile;Italy;South Africa;Brazil;India;United Kingdom;Canada;Peru;Mexico;Argentina;Romania;Spain;Thailand;United States;Philippines;Poland
4EUCTR2010-024069-30-IT
(EUCTR)
05/07/201119/01/2012A study to investigate the optimum dose, the efficacy and the safety of sifalimumab in adult patients with Systemic Lupus Erythematosus, a disease of the immune systemA Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults with Systemic Lupus Erythematosus Systemic Lupus Erythematosus
MedDRA version: 14.1;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Sifalimumab
Product Code: MEDI-545
INN or Proposed INN: sifalimumab
ASTRAZENECANULLNot RecruitingFemale: yes
Male: yes
544Phase 2United States;Philippines;Spain;Thailand;Chile;United Kingdom;Italy;India;Hungary;Mexico;Canada;Argentina;Brazil;Peru;Bulgaria;South Africa;Germany;Netherlands
5EUCTR2010-024069-30-ES
(EUCTR)
19/05/201119/05/2011A study to investigate the optimum dose, the efficacy and the safety of sifalimumab in adult patients with Systemic Lupus Erythematosus, a disease of the immune systemA Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults with Systemic Lupus Erythematosus Systemic Lupus Erythematosus
MedDRA version: 13.1;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Sifalimumab
Product Code: MEDI-545
INN or Proposed INN: sifalimumab
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
544Phase 2United States;Philippines;Spain;Thailand;Chile;Italy;United Kingdom;India;France;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Romania;Peru;Bulgaria;South Africa;Germany;Netherlands
6EUCTR2010-024069-30-GB
(EUCTR)
18/05/201113/05/2011A study to investigate the optimum dose, the efficacy and the safety of sifalimumab in adult patients with Systemic Lupus Erythematosus, a disease of the immune systemA Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults with Systemic Lupus Erythematosus Systemic Lupus Erythematosus
MedDRA version: 14.1;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Sifalimumab
Product Code: MEDI-545
INN or Proposed INN: sifalimumab
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
400Phase 2Romania;Peru;Bulgaria;South Africa;Netherlands;Germany;Brazil;United States;Philippines;Spain;Thailand;Chile;Italy;United Kingdom;India;France;Hungary;Mexico;Canada;Argentina;Poland
7NCT00979654
(ClinicalTrials.gov)
August 201017/9/2009A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or MyositisA Phase 2 Open-label Study to Evaluate the Long-term Safety of Sifalimumab in Adult Subjects With Systemic Lupus Erythematosus or MyositisSystemic Lupus ErythematosusDrug: SifalimumabMedImmune LLCPPDCompleted18 Years99 YearsAll118Phase 2United States;Brazil;Canada;Chile
8NCT01031836
(ClinicalTrials.gov)
November 25, 200911/12/2009A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.A Phase II, Multicenter, Open-Label, Dose-Escalation Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545, a Fully Human Monoclonal Antibody Directed Against Interferon Alpha Subtypes, in Japanese Patients Who Have Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythematosusDrug: MEDI-545;Drug: MEDI-545 600AstraZenecaMedImmune LLCCompleted20 Years130 YearsAll30Phase 2Japan
9NCT00657189
(ClinicalTrials.gov)
July 20089/4/2008A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With LupusA Phase 2A , Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Dose Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Doses of MEDI-545, A Fully Human Anti-Interferon-Alpha Monoclonal Antibody, In Subjects With Systemic Lupus ErythematosusLupus Erythematosus, Systemic;LupusDrug: MEDI-545;Drug: PlaceboMedImmune LLCNULLCompleted18 YearsN/ABoth87Phase 2United States
10NCT00482989
(ClinicalTrials.gov)
June 20074/6/2007A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus ErythematosusA Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI-545, a Fully Human Anti-Interferon-Alpha Monoclonal Antibody, in Patients With Systemic Lupus ErythematosusLupusBiological: MEDI 545;Other: PlaceboMedImmune LLCNULLCompleted18 YearsN/ABoth183Phase 1United States;Argentina;Brazil;Chile;Canada
11NCT00299819
(ClinicalTrials.gov)
March 20066/3/2006Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)A Phase I, Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate Safety and Tolerability of a Single IV Dose of MEDI-545, a Fully Human Monoclonal Antibody Directed Against Interferon Alpha Subtypes, in Patients With Systemic Lupus Erythematosus (SLE)LupusBiological: MEDI-545;Biological: MEDI 545MedImmune LLCNULLCompleted18 Years80 YearsBoth45Phase 1United States;Canada
12EUCTR2010-024069-30-HU
(EUCTR)
17/05/2011A study to investigate the optimum dose, the efficacy and the safety of sifalimumab in adult patients with Systemic Lupus Erythematosus, a disease of the immune systemA Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults with Systemic Lupus Erythematosus Systemic Lupus Erythematosus
MedDRA version: 14.1;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Sifalimumab
Product Code: MEDI-545
INN or Proposed INN: sifalimumab
AstraZeneca ABNULLNot RecruitingFemale: yes
Male: yes
400Phase 2United States;Philippines;Spain;Thailand;Chile;Italy;United Kingdom;India;France;Hungary;Mexico;Canada;Argentina;Poland;Brazil;Romania;Peru;South Africa;Bulgaria;Netherlands;Germany